Epstein Secrets

s): Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Merck & Co., Inc.. • Non-Investment Banking Compensation: M. Morgan has received compensation in the past 12 months for products or services other than investment banking from Merck & Co., Inc.. Company-S

erage universe. If it does not appear in the Ira runt Disclosures section of this report, the cettifying analyst's coverage universe can be found on M. Morgan's research website, Coverage Universe: Schott, Christopher: AbbVie (ABBV), Actavis plc (ACT), Allergan (AGN), Amarin Corporation (AMRN), Bristol-Mye

y-14 OW 57.11 64.00 4 EFTA00306886 Chris Schott. CFA North America Equity Research 1-21 622-5676 02 June 2014 J.P.Morgan The chart(s) show M. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire riot M. Morgan ratings or designations: OW -

: J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Gilead Sciences. • Non-Investment Banking Compensation: J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Gilead Sciences. Company-S

OW 72.67 85.00 18-0ec-13 OW 73.59 100.00 EFTA00300342 Coon Ktorerom North America Equity Research 22 May 2014 J.RMorgan The chart(s) show M. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire period. J.P. Morgan ratings or designations:

e, or intends to seek, compensation for investment banking services in the next three months from Bristol-M rs Squibb Company, Merck & Co., Inc.. • Non-Investment Banking Compensation: Morgan has received compensation in the past 12 months for products or services other than investment banking from Bristol-Myers Squibb Company, M

4 OW 57.11 64.00 10-Oct-14 OW 59.21 66.00 20-Jan-15 OW 63.03 68.00 21-Sep-15 OW 52.13 65.00 30-Sep-15 OW 49.39 66.00 The chart(s) show M. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire M. Morgan ratings or designations: OW Overwei